CLDN18 and cancer: The monoclonal antibody claudiximab (IMAB362, zolbetuximab) targets the membranous CLDN18.2 isoform27 and induces cancer cell apoptosis and immune effectors by activating antibody‐dependent cellular cytotoxicity (ADCC) and complement‐dependent cytotoxicity (CDC).28